Rituximab for Pediatric Central Nervous System Inflammatory Disorders in Alberta, Canada

Autor: Pecuh, Ihor, Slobodan, Jeremy, McCombe, Jennifer A., Morneau-Jacob, Francois-Dominique, Smyth, Penelope, Wilbur, Colin
Zdroj: The Canadian Journal of Neurological Sciences; January 2024, Vol. 51 Issue: 1 p50-56, 7p
Abstrakt: ABSTRACT:Background:Early and effective treatment of central nervous system (CNS) inflammatory disorders is vital to reduce neurologic morbidity and improve long-term outcomes in affected children. Rituximab is a B-cell-depleting monoclonal antibody whose off-label use for these disorders is funded in the province of Alberta, Canada, by the Short-Term Exceptional Drug Therapy (STEDT) program. This study describes the use of rituximab for pediatric CNS inflammatory disorders in Alberta.Methods:Rituximab applications for CNS inflammatory indications in patients <18 years of age were identified from the STEDT database between January 1, 2012, and December 31, 2019. Patient information was linked to other provincial datasets including the Discharge Abstract Database, Pharmaceutical Information Network, and Provincial Laboratory data. Analysis was descriptive.Results:Fifty-one unique rituximab applications were identified, of which 50 were approved. New applications increased from one in 2012 to a high of 12 in 2018. The most common indication was autoimmune encephalitis without a specified antibody (n= 16, 31%). Most children were approved for a two-dose (n= 33, 66%) or four-dose (n= 16, 32%) induction regimen. Physician-reported outcomes were available for 24 patients, of whom 14 (58%) were felt to have fully met outcome targets.Conclusion:The use of rituximab for pediatric CNS inflammatory disorders has increased, particularly for the indication of autoimmune encephalitis. This study identified significant heterogeneity in dosing practices and laboratory monitoring. Standardized protocols for the use of rituximab in these disorders and more robust outcome reporting will help better define the safety and efficacy of rituximab in this population
Databáze: Supplemental Index